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pages on lung carcinoma, and Taxy &
Battifora's 70 pages on soft-tissue tumours
(each with an impressive reference list of
almost 200 citations) will be welcomed by
workers in these fields as major reviews. The
tumour theme is further explored in a shorter
but none the less pertinent and valuable
account of prostatic carcinoma by Tannen-
baum & Tannenbaum, a chapter interesting
forits inclusion ofscanning EM as a diagnosti-
cally useful technique in an area where the
transmission mode predominates.
Churg, Spargo, Sakaguchi & Jones' detailed
appraisal of one of the earliest and most
important areas of application ("Diagnostic
Electron Microscopy of Renal Disease") is a
substantial account of over 100 pages and is
lavishly illustrated (most illustrations being
of full-page size). It will be essential reading
for any histopathologist encountering renal
material, though, despite its title, the
chapter omits neoplastic conditions of the
kidney. Wood & Hu's "Diagnostic Electron
Microscopy of the Skin", covers neoplastic
and non-neoplastic conditions. This is an
excellent treatment ofthe subject, with some
exceptionally fine illustrations. The volume
culminates in a comprehensive treatment by
Bloodworth, Horvath & Kovacs on the "Fine
Structural Pathology of the Endocrine Sys-
tem". This chapter, in keeping intellectually
and presentationally with the rest of the
volume, must be considered a significant
contribution to this field.
"Diagnostic Electron Microscopy volume
3", in summary, will provide histopatholo-
gists with access to or an interest in electron
microscopy with authoritative treatments
of several major areas of tumour and non-
tumour application: it will be particularly
welcomed by those specializing in neoplasia.
The price of over £50 cannot be considered
high for such a quality volume of over 500
pages.
B. EDEN
New Frontiers in Mammary Pathology.
Eds K. H. HOLLMAN, J. DE BRUX &
J. M. VERLEY (1981). London: Plenum
Press. 319 pp. £39.50 net.
This sort of book should not be published.
It is the proceedings of a symposium held in
Paris in December, 1979 and had reached the
bookshops in 1981 at the exhorbitant price
of £39.50. The papers were all by invited
speakers (9 from France; 2 from Belgium;
2 from U.S.A.; one each from U.K. and
Switzerland) and, whilst some of the work
described was recent or in progress, many of
the "frontiers" being reviewed were passed
well before the conference took place. Indeed
in some sections, e.g. those on "The Natural
History of Benign Breast Tumours" and on
"Cystosarcoma phyllodes", there are no new
ideas or observations at all, merely pedestrian
accounts which would scarcely be adequate
in a standard text book.
There is little in this book which cannot be
found elsewhere in the literature and I
advise you not to buy it.
M. HARRIS
WHO Handbook for Reporting Results of
Cancer Treatment. WHO Publication
No. 48 (1979). Geneva: WHO. 45 pp.
6 Sw. Fr. net.
There has been an enormous expansion of
cancer literature in recent decades as a
result of the large number of clinical trials
and other studies carried out throughout the
world. Comparisons of the results of such
studies are often made difficult because of
the lack of a "common language". This
WHO handbook (and an article in Cancer,
47, 207, 1981) arose from 2 meetings of
international experts from many disciplines,
and sets out some generally acceptable
principles for evaluating data and reporting
results. The first chapter deals with the
minimum amount of data that should be
recorded as regards patient characteristics,
the tumour, and laboratory and radio-
logical investigations. The next chapter
deals with describing treatment details and
here the committee suggests the term
"adjuvant therapy" should not be used since
what is considered adjuvant to primary
treatment today may become primary treat-
ment tomorrow. Instead "combined modality
therapy" is recommended.
Other chapters cover the grading of toxic
effects and response: the definitions recom-
mended are those which have been in general
use for the last few years. In many trials
first recurrence is an important end-point,
but determining the date on which it occurred
can be difficult: the committee recommends